Modality
mAb
MOA
HER2
Target
Aβ
Pathway
Angiogenesis
FTDEpilepsy
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
~Oct 2018
→ ~Jan 2020
Phase 3
Apr 2020
→ Jul 2028
Phase 3Current
NCT06911553
1,538 pts·Epilepsy
2021-11→2025-03·Recruiting
NCT03343567
2,811 pts·FTD
2024-12→2027-07·Terminated
NCT05455573
2,862 pts·FTD
2024-10→2028-07·Completed
+1 more trial
9,847 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-03-051.1y agoPh3 Readout· Epilepsy
2027-02-0510mo awayPh3 Readout· FTD
2027-07-071.3y awayPh3 Readout· FTD
2028-07-152.3y awayPh3 Readout· FTD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Recruit…
P3
Complet…
P3
Termina…
Catalysts
Ph3 Readout
2025-03-05 · 1.1y ago
Epilepsy
Ph3 Readout
2027-02-05 · 10mo away
FTD
Ph3 Readout
2027-07-07 · 1.3y away
FTD
Ph3 Readout
2028-07-15 · 2.3y away
FTD
RecruitingCompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06911553 | Phase 3 | Epilepsy | Recruiting | 1538 | UPDRS |
| NCT03343567 | Phase 3 | FTD | Terminated | 2811 | CfB |
| NCT05455573 | Phase 3 | FTD | Completed | 2862 | Mayo |
| NCT08641356 | Phase 3 | FTD | Not yet recr... | 2636 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ |